Tuesday, April 19, 2022

UK-based CRO Charnwood Molecular reveals plans for ‘significant’ expansion in 2021

UK-based contract research organisation (CRO) Charnwood Molecular has revealed its plans for expansion in 2021, which includes becoming the sole occupier of a ‘substantial’ laboratory facility in Loughborough.

Charnwood Molecular recently announced a partnership with private equity fund Synoya to further its expansion plans.

This deal, according to the CRO, provided additional capital to support the company’s future development and growth, including hiring additional senior leadership team members.

The expansion plans include Charnwood Molecular becoming the sole occupier of a ‘state-of-the-art’ laboratory facility at Charnwood Campus, based in Loughborough.

This campus was recently designated a ‘Life Sciences Opportunity Zone’, Charnwood Molecular said in a statement, allowing for greater collaboration and accelerated business growth within the med-tech and biopharma industries.

The company’s expansion plans will support its growth across a wide range of contract research services, such as medicinal chemistry, chemical development and early process research through to developing a suite of complementary services.

“The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector,” said Steve Allin, chief executive officer of Charnwood Molecular.

“The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines,” he added.

“Our expansion plans for the business are now coming to fruition.  From hiring significant numbers of new scientists at both of our existing research sites, through to a doubling of our business development team and now adding much larger bespoke facilities, we are looking to the future to make Charnwood Molecular a very major player in the discovery CRO marketplace,” added John Handley, managing director of Charnwood Molecular.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...